APA (7th ed.) Citation

Coutant, D. E., Rehmel, J., Edwards, D. M., & Hall, S. D. (2025). A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker. European Journal of Clinical Pharmacology, 81(6), 853-862. https://doi.org/10.1007/s00228-025-03839-1

Chicago Style (17th ed.) Citation

Coutant, David E., Jessica Rehmel, Donna M. Edwards, and Stephen D. Hall. "A Novel Physiologically-based Pharmacokinetic Model to Estimate Reduced CYP3A4 Activity in Cancer Patients Utilizing the Neutrophil-to-lymphocyte Ratio as an Inflammatory Marker." European Journal of Clinical Pharmacology 81, no. 6 (2025): 853-862. https://doi.org/10.1007/s00228-025-03839-1.

MLA (9th ed.) Citation

Coutant, David E., et al. "A Novel Physiologically-based Pharmacokinetic Model to Estimate Reduced CYP3A4 Activity in Cancer Patients Utilizing the Neutrophil-to-lymphocyte Ratio as an Inflammatory Marker." European Journal of Clinical Pharmacology, vol. 81, no. 6, 2025, pp. 853-862, https://doi.org/10.1007/s00228-025-03839-1.